The GIP Question: Why Tirzepatide’s Second Receptor Matters to Researchers

When tirzepatide arrived, much of the attention went to its results. The more intriguing scientific question was why it worked so well. Tirzepatide activates two receptors, GLP-1 and GIP, and for years many researchers were unsure whether GIP activity would help at all. Tirzepatide has forced the field to look at GIP again, and the answers are still being worked out in the lab.

What GIP does

GIP (glucose-dependent insulinotropic polypeptide) is a hormone released by the gut after eating. Like GLP-1, it helps the pancreas release insulin when blood sugar rises. It also acts on fat tissue, where it influences how fat is stored and handled, and it has receptors in parts of the brain involved in appetite and nausea.

For a long time, GIP was seen as the less useful of the two hormones, because its insulin effect appears weaker in people with type 2 diabetes. That made tirzepatide’s strong results something of a surprise, and it reopened an old debate.

The GIP paradox

Here is the puzzle researchers are still working through. Tirzepatide activates the GIP receptor and produces large metabolic effects. Yet some other experimental compounds that block the GIP receptor, combined with GLP-1 activity, have also shown substantial weight loss in early trials.

Several explanations are being studied. Long-term activation of the GIP receptor may eventually make it less responsive, so activating and blocking it could end up having similar effects over time. GIP activity in the brain may reduce the nausea that GLP-1 compounds can cause. And tirzepatide behaves differently at the GLP-1 receptor than natural GLP-1 does, which may matter as much as its GIP activity.

Insulin sensitivity beyond weight loss

Clinical studies using specialised techniques to measure insulin action have suggested that tirzepatide improves insulin sensitivity and the function of insulin-producing cells, and that part of this improvement is not fully explained by weight loss alone. Those findings point towards direct effects of the dual receptor signal on tissues such as muscle, fat and the pancreas.

Where laboratory research comes in

Questions like these are well suited to cell and tissue models, where each receptor’s contribution can be studied separately. Areas of active research include:

• How fat cells respond to combined GLP-1 and GIP activity compared with either one alone.
• Whether long-term GIP receptor activation changes how responsive the receptor stays.
• How tirzepatide’s signalling at the GLP-1 receptor differs from that of natural GLP-1 and older compounds.
• How a dual agonist compares with newer triple agonists such as retatrutide in the same model.

A clear introduction to how tirzepatide works and how it compares with other incretin peptides is available in the Tirzepatide UK research guide.

Sourcing research-grade tirzepatide

Tirzepatide is licensed in the UK as a prescription medicine under the brand name Mounjaro. Research chemical suppliers separately provide it strictly for laboratory use. For receptor studies in particular, purity and accurate peptide content are essential. Look for an independent certificate of analysis from a recognised lab such as Janoshik, matched to the batch, with purity of 98% or above.

UK suppliers such as Revial Labs tirzepatide stock the compound in the UK, send it by tracked delivery and publish independent test results for their batches.

The bottom line

Tirzepatide has turned GIP from a footnote into one of the most debated hormones in metabolic science. Whether its benefits come mainly from GIP activity, from the way it acts at the GLP-1 receptor, or from the combination, is a question laboratory research is well placed to answer.

This article is for information only. Tirzepatide supplied by research chemical companies is for laboratory research use only and is not for human consumption.